<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03838185</url>
  </required_header>
  <id_info>
    <org_study_id>ABRJ147001</org_study_id>
    <nct_id>NCT03838185</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147 in Healthy Young Volunteers and Healthy Elderly Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abrexa Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abrexa Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I clinical study is a randomized, double-blind, placebo-controlled,&#xD;
      parallel-design study to thoroughly assess the safety profile and PK properties of J147 in&#xD;
      healthy subjects. The study will include single ascending dose (SAD) in healthy young and&#xD;
      elderly subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase I clinical study is a randomized, double-blind, placebo-controlled,&#xD;
      parallel-design study to thoroughly assess the safety profile and PK properties of J147 in&#xD;
      healthy subjects and to perform a preliminary assessment of the effect of food on safety and&#xD;
      PK parameters of J147. The study will include single ascending dose (SAD) in healthy young&#xD;
      and elderly subjects.&#xD;
&#xD;
      Approximately 64 subjects may be included in the study, with an additional 24 to be added&#xD;
      depending on the emerging data.&#xD;
&#xD;
      Six cohorts of 8 healthy young male subjects and 2 cohorts of 8 healthy elderly male and&#xD;
      female subjects are planned. Depending on emerging safety, tolerability and PK data, 2&#xD;
      additional cohorts of 8 healthy young male subjects in each cohort and 1 additional cohort of&#xD;
      8 elderly male and female subjects may be enrolled.&#xD;
&#xD;
      In each cohort, 6 subjects will be randomized to receive a single dose of J147 orally and 2&#xD;
      subjects will be randomized to receive a matching dose of placebo.&#xD;
&#xD;
      All cohorts will consist of 2 sentinel subjects of whom 1 subject will receive J147 and 1&#xD;
      subject will receive matching placebo. The remaining 6 subjects of whom 5 subjects will&#xD;
      receive J147 and 1 subject will receive matching placebo will be dosed at least 24 hours&#xD;
      following the sentinel subjects.&#xD;
&#xD;
      Healthy elderly subjects will receive doses that have been found to be safe in healthy young&#xD;
      subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Actual">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Subjects will receive a single dose of J147 or placebo in a fasted state. The dose levels are planned to be administered in ascending order. Progression to the next dose level, and dose selection, will be based on all available safety and tolerability data up to at least 48 hours post-dose and available PK data (up to at least 24 hours post-dose) from a minimum of 6 subjects (J147 n ≥4) in the preceding dose cohort. Healthy elderly subjects will receive doses that have been found to be safe in healthy young subjects.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>from pre-dose to 7+/-2 days post dose</time_frame>
    <description>Nature, frequency and severity of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal electrocardiogram</measure>
    <time_frame>from pre-dose to 7+/-2 days post dose</time_frame>
    <description>12-lead electrocardiogram measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in serum biomarker levels in a standard serum chemistry panel</measure>
    <time_frame>from pre-dose to 7+/-2 days post dose</time_frame>
    <description>Changes in standard serum chemistry measures will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in hematological biomarker levels in a standard hematology panel</measure>
    <time_frame>from pre-dose to 7+/-2 days post dose</time_frame>
    <description>Changes in standard hematology measures will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in urine biomarker levels in a standard urinalysis panel</measure>
    <time_frame>from pre-dose to 7+/-2 days post dose</time_frame>
    <description>Changes in standard urinalysis measures will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients exhibiting changes in standard Physical Examination results</measure>
    <time_frame>from pre-dose to 7+/-2 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients exhibiting changes in standard Neurological Examination results</measure>
    <time_frame>from pre-dose to 7+/-2 days post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>0-48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>0-48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration vs. time curve (AUC)</measure>
    <time_frame>0-48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant</measure>
    <time_frame>0-48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>0-48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent plasma clearance (CL/F)</measure>
    <time_frame>0-48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLr)</measure>
    <time_frame>0-48 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Study Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy young male subjects will receive a single ascending oral dose of J147 following an overnight fast of at least 8 hours. Healthy elderly subjects will receive doses that have been found to be safe in healthy young subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a single oral dose of placebo with 240 mL non-carbonated water in the morning following an overnight fast of at least 8 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>J147</intervention_name>
    <description>Single oral dose of J147</description>
    <arm_group_label>Study Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single oral dose of corn oil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide voluntarily agreement to participate in this study and signs an&#xD;
             IRB/IEC-approved informed consent prior to performing any of the screening procedures&#xD;
&#xD;
          -  Healthy male subjects, between 18 to 50 years of age, inclusive, at the time of&#xD;
             signing the informed consent; OR, Healthy male and female subjects, between 60 to 85&#xD;
             years of age, inclusive, at the time of signing the informed consent&#xD;
&#xD;
          -  If male, subjects with partners of child bearing potential must be practicing&#xD;
             abstinence, part of an abstinent life style or agree to use a highly effective&#xD;
             contraception method during the intervention period and for at least 3 months after&#xD;
             the last dose of study medication and refrain from donating sperm during this period.&#xD;
             Because of the unacceptable failure rate of barrier (chemical and/or physical)&#xD;
             methods, the barrier method of contraception must only be used in combination with a&#xD;
             highly effective method. Post coital methods of contraception are not permitted.&#xD;
&#xD;
          -  If female, must not be pregnant, must not be lactating, and must be of&#xD;
             non-childbearing potential (surgically sterile [hysterectomy or bilateral tubal&#xD;
             ligation] or postmenopausal ≥ 1 year.&#xD;
&#xD;
          -  Body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive, at screening with a&#xD;
             weight of at least 50 kg&#xD;
&#xD;
          -  Nonsmokers (or other nicotine use) as determined by history (no nicotine use over the&#xD;
             past year) and by urine cotinine concentration (&lt; 200 ng/mL) at the screening visit&#xD;
             and admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has clinically significant history or evidence of cardiovascular, endocrine,&#xD;
             hematologic, immune, gastrointestinal, genitourinary or other body system disease as&#xD;
             determined by an Investigator&#xD;
&#xD;
          -  Has clinically significant history or evidence of disease or dysfunction in&#xD;
             neurological or psychiatric system that is likely to affect the results of the study&#xD;
             in the opinion of an Investigator&#xD;
&#xD;
          -  Has any disorder that would interfere with the absorption, distribution, metabolism or&#xD;
             excretion of drugs&#xD;
&#xD;
          -  Subject has any concurrent disease or condition that, in the opinion of the Principal&#xD;
             Investigator, would make the subject unsuitable for participation in the clinical&#xD;
             study&#xD;
&#xD;
          -  Has positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV)&#xD;
             or human immunodeficiency virus (HIV) antibodies&#xD;
&#xD;
          -  Has a urine blood test for ethanol or cotinine at the screening visit or admission&#xD;
&#xD;
          -  Has a positive urine drug test (e.g., cocaine, amphetamines, barbiturates, opiates,&#xD;
             benzodiazepines, cannabinoids) at the screening visit or admission&#xD;
&#xD;
          -  Females who are breastfeeding&#xD;
&#xD;
          -  Is unwilling to or has not avoided consumption of grapefruit, grapefruit juice,&#xD;
             Seville oranges, Seville orange marmalade or other products containing grapefruit or&#xD;
             Seville oranges within 14 days of dosing with study medication&#xD;
&#xD;
          -  Has history of alcohol and/or illicit drug abuse within 1 year of entry or is&#xD;
             unwilling to avoid use of alcohol or alcohol-containing foods, medications or&#xD;
             beverages, within 48 hours prior to admission until discharge from the clinical unit&#xD;
&#xD;
          -  Has donated blood (&gt; 500 mL) or blood products within 30 days prior to first day of&#xD;
             dosing&#xD;
&#xD;
          -  Requires treatment with any medication, prescription or over-the-counter (OTC)&#xD;
             medications (including vitamins [mega doses], dietary supplements or herbal&#xD;
             medications), prescription medications within 14 days prior to administration of study&#xD;
             medication. By exception, acetaminophen ≤ 1000 mg per day and vitamin products at&#xD;
             recommended daily doses are permitted&#xD;
&#xD;
          -  Has received any known hepatic or renal clearance altering agents (e.g., erythromycin,&#xD;
             cimetidine, barbiturates, phenothiazines or herbal/plant-derived preparations such as&#xD;
             St. John's wort) for a period of 30 days prior to dosing&#xD;
&#xD;
          -  Has used an investigational drug within 30 days prior to screening&#xD;
&#xD;
          -  Has a history of hypersensitivity or allergies to J147, any components of formulated&#xD;
             J147, or any drug within the same class; minor drug allergies to a drug in another&#xD;
             drug class may be approved by an Investigator if not considered of clinical relevance&#xD;
&#xD;
          -  Has clinically significant abnormal vital signs, 12-lead ECGs, physical examination,&#xD;
             clinical laboratory, or other safety variable, as judged by an Investigator&#xD;
&#xD;
          -  Is considering or has scheduled any surgical procedure during study participation&#xD;
&#xD;
          -  Requires a special diet or has a significant food allergy or intolerance; if the&#xD;
             subject or patient is vegetarian, he or she may be enrolled at an Investigator's&#xD;
             discretion&#xD;
&#xD;
          -  Is unable to understand the protocol requirements, instructions and study related&#xD;
             restrictions, the nature, scope and possible consequences of the clinical study&#xD;
&#xD;
          -  Is unlikely to comply with the protocol requirements, instructions and study related&#xD;
             restrictions; e.g., uncooperative attitude, inability to return for follow-up visits&#xD;
             and improbability of completing the clinical study&#xD;
&#xD;
          -  Has previously been enrolled in this clinical study or is currently enrolled in&#xD;
             another clinical study&#xD;
&#xD;
          -  For the elderly subjects, there must be no evidence of cognitive decline that has been&#xD;
             greater than expected for age and no evidence of changes in their level of&#xD;
             independence in everyday life.&#xD;
&#xD;
          -  Is judged by an Investigator or Sponsor to be inappropriate for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Kankam, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vince &amp; Associates Clinical Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chen Q, Prior M, Dargusch R, Roberts A, Riek R, Eichmann C, Chiruta C, Akaishi T, Abe K, Maher P, Schubert D. A novel neurotrophic drug for cognitive enhancement and Alzheimer's disease. PLoS One. 2011;6(12):e27865. doi: 10.1371/journal.pone.0027865. Epub 2011 Dec 14.</citation>
    <PMID>22194796</PMID>
  </reference>
  <reference>
    <citation>Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimers Res Ther. 2013 May 14;5(3):25. doi: 10.1186/alzrt179. eCollection 2013.</citation>
    <PMID>23673233</PMID>
  </reference>
  <reference>
    <citation>Currais A, Goldberg J, Farrokhi C, Chang M, Prior M, Dargusch R, Daugherty D, Armando A, Quehenberger O, Maher P, Schubert D. A comprehensive multiomics approach toward understanding the relationship between aging and dementia. Aging (Albany NY). 2015 Nov;7(11):937-55. doi: 10.18632/aging.100838.</citation>
    <PMID>26564964</PMID>
  </reference>
  <reference>
    <citation>Prior M, Goldberg J, Chiruta C, Farrokhi C, Kopynets M, Roberts AJ, Schubert D. Selecting for neurogenic potential as an alternative for Alzheimer's disease drug discovery. Alzheimers Dement. 2016 Jun;12(6):678-86. doi: 10.1016/j.jalz.2016.03.016. Epub 2016 May 2.</citation>
    <PMID>27149904</PMID>
  </reference>
  <reference>
    <citation>Goldberg J, Currais A, Prior M, Fischer W, Chiruta C, Ratliff E, Daugherty D, Dargusch R, Finley K, Esparza-Molto PB, Cuezva JM, Maher P, Petrascheck M, Schubert D. The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell. 2018 Apr;17(2):e12715. doi: 10.1111/acel.12715. Epub 2018 Jan 7.</citation>
    <PMID>29316249</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia</keyword>
  <keyword>Neurodegenerative Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03838185
org study id: ABRJ147001
nct id: NCT03838185
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This Phase I clinical study is a randomized, double-blind, placebo-controlled,
      parallel-design study to thoroughly assess the safety profile and PK properties of J147 in
      healthy subjects. The study will include single ascending dose (SAD) in healthy young and
      elderly subjects.
This Phase I clinical study is a randomized, double-blind, placebo-controlled,
      parallel-design study to thoroughly assess the safety profile and PK properties of J147 in
      healthy subjects and to perform a preliminary assessment of the effect of food on safety and
      PK parameters of J147. The study will include single ascending dose (SAD) in healthy young
      and elderly subjects.

      Approximately 64 subjects may be included in the study, with an additional 24 to be added
      depending on the emerging data.

      Six cohorts of 8 healthy young male subjects and 2 cohorts of 8 healthy elderly male and
      female subjects are planned. Depending on emerging safety, tolerability and PK data, 2
      additional cohorts of 8 healthy young male subjects in each cohort and 1 additional cohort of
      8 elderly male and female subjects may be enrolled.

      In each cohort, 6 subjects will be randomized to receive a single dose of J147 orally and 2
      subjects will be randomized to receive a matching dose of placebo.

      All cohorts will consist of 2 sentinel subjects of whom 1 subject will receive J147 and 1
      subject will receive matching placebo. The remaining 6 subjects of whom 5 subjects will
      receive J147 and 1 subject will receive matching placebo will be dosed at least 24 hours
      following the sentinel subjects.

      Healthy elderly subjects will receive doses that have been found to be safe in healthy young
      subjects.
allocation: Randomized
intervention model: Sequential Assignment
intervention model description: Subjects will receive a single dose of J147 or placebo in a fasted state. The dose levels are planned to be administered in ascending order. Progression to the next dose level, and dose selection, will be based on all available safety and tolerability data up to at least 48 hours post-dose and available PK data (up to at least 24 hours post-dose) from a minimum of 6 subjects (J147 n ≥4) in the preceding dose cohort. Healthy elderly subjects will receive doses that have been found to be safe in healthy young subjects.
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Incidence of treatment-emergent adverse events
time frame: from pre-dose to 7+/-2 days post dose
description: Nature, frequency and severity of adverse events
measure: Number of subjects with abnormal electrocardiogram
time frame: from pre-dose to 7+/-2 days post dose
description: 12-lead electrocardiogram measurement
measure: Incidence of clinically significant changes in serum biomarker levels in a standard serum chemistry panel
time frame: from pre-dose to 7+/-2 days post dose
description: Changes in standard serum chemistry measures will be assessed.
measure: Incidence of clinically significant changes in hematological biomarker levels in a standard hematology panel
time frame: from pre-dose to 7+/-2 days post dose
description: Changes in standard hematology measures will be assessed.
measure: Incidence of clinically significant changes in urine biomarker levels in a standard urinalysis panel
time frame: from pre-dose to 7+/-2 days post dose
description: Changes in standard urinalysis measures will be assessed.
measure: Number of patients exhibiting changes in standard Physical Examination results
time frame: from pre-dose to 7+/-2 days post dose
measure: Number of patients exhibiting changes in standard Neurological Examination results
time frame: from pre-dose to 7+/-2 days post dose
measure: Maximum plasma concentration (Cmax)
time frame: 0-48 hours post dose
measure: Time to Cmax (Tmax)
time frame: 0-48 hours post dose
measure: Area under the plasma concentration vs. time curve (AUC)
time frame: 0-48 hours post dose
measure: Terminal rate constant
time frame: 0-48 hours post dose
measure: Terminal half-life (t1/2)
time frame: 0-48 hours post dose
measure: Apparent plasma clearance (CL/F)
time frame: 0-48 hours post dose
measure: Renal clearance (CLr)
time frame: 0-48 hours post dose
arm group label: Study Drug
arm group type: Experimental
description: Healthy young male subjects will receive a single ascending oral dose of J147 following an overnight fast of at least 8 hours. Healthy elderly subjects will receive doses that have been found to be safe in healthy young subjects.
arm group label: Placebo
arm group type: Placebo Comparator
description: Subjects will receive a single oral dose of placebo with 240 mL non-carbonated water in the morning following an overnight fast of at least 8 hours.
intervention type: Drug
intervention name: J147
description: Single oral dose of J147
arm group label: Study Drug
intervention type: Drug
intervention name: Placebo
description: Single oral dose of corn oil
arm group label: Placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: 85 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Martin Kankam, MD, PhD, MPH
role: Principal Investigator
affiliation: Vince & Associates Clinical Research, Inc.
facility: 
country: United States
citation: Chen Q, Prior M, Dargusch R, Roberts A, Riek R, Eichmann C, Chiruta C, Akaishi T, Abe K, Maher P, Schubert D. A novel neurotrophic drug for cognitive enhancement and Alzheimer's disease. PLoS One. 2011;6(12):e27865. doi: 10.1371/journal.pone.0027865. Epub 2011 Dec 14.
PMID: 22194796
citation: Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimers Res Ther. 2013 May 14;5(3):25. doi: 10.1186/alzrt179. eCollection 2013.
PMID: 23673233
citation: Currais A, Goldberg J, Farrokhi C, Chang M, Prior M, Dargusch R, Daugherty D, Armando A, Quehenberger O, Maher P, Schubert D. A comprehensive multiomics approach toward understanding the relationship between aging and dementia. Aging (Albany NY). 2015 Nov;7(11):937-55. doi: 10.18632/aging.100838.
PMID: 26564964
citation: Prior M, Goldberg J, Chiruta C, Farrokhi C, Kopynets M, Roberts AJ, Schubert D. Selecting for neurogenic potential as an alternative for Alzheimer's disease drug discovery. Alzheimers Dement. 2016 Jun;12(6):678-86. doi: 10.1016/j.jalz.2016.03.016. Epub 2016 May 2.
PMID: 27149904
citation: Goldberg J, Currais A, Prior M, Fischer W, Chiruta C, Ratliff E, Daugherty D, Dargusch R, Finley K, Esparza-Molto PB, Cuezva JM, Maher P, Petrascheck M, Schubert D. The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell. 2018 Apr;17(2):e12715. doi: 10.1111/acel.12715. Epub 2018 Jan 7.
PMID: 29316249
responsible party type: Sponsor
mesh term: Alzheimer Disease
sharing ipd: Undecided